NEWS

2023-09-13

Provides clinical validation for ACM Biolab's Tunable Platform (ATP™), ACM Biolab's proprietary polymer-based delivery platform. ACM-001 was well tolerated at the recommended dose levels with no serious adverse events and encouraging early immunogenicity data. ACM is in partnering discussions to provide new drug delivery solutions that address the most significant challenges faced using lipid...